Ethris's Inhaled mRNA Therapy Shows Promise in Phase 1 Asthma Trial
Ethris, a Munich-based biotechnology company, has achieved a significant milestone in the development of messenger RNA (mRNA) therapeutics for respiratory conditions with positive Phase 1 results for its lead candidate ETH47, designed to treat uncontrolled asthma.
The clinical trial, which enrolled 40 healthy volunteers, demonstrated that the inhaled mRNA therapeutic was both safe and well-tolerated across all tested dose levels. Notably, no severe adverse events were reported, and no participants discontinued treatment during the study.
Novel Mechanism Targets Viral Triggers
ETH47 represents an innovative approach to treating uncontrolled asthma, a condition characterized by frequent and disruptive symptoms often triggered by viral infections. The therapy works by delivering mRNA that encodes interferon lambda (IFNλ), a protein crucial for maintaining antiviral immunity in the respiratory tract.
The study revealed a dose-dependent production of IFNλ in the nasal lining fluid, achieving the desired local immune response. Importantly, neither the mRNA therapeutic nor the produced IFNλ was detected systemically, supporting the company's strategy to minimize off-target effects through precise delivery to the respiratory tract.
Clinical Implications and Expert Insights
"These positive phase 1 results reinforce the promise of ETH47 as a potentially safe and transformative treatment option for asthma patients," stated Thomas Langenickel, Chief Medical Officer at Ethris. He emphasized that the results also validate their proprietary technology platform for delivering mRNA therapeutics to the respiratory tract.
The successful trial outcomes demonstrate the platform's capability to facilitate targeted protein production exactly where needed, marking a crucial advancement in respiratory mRNA therapeutics.
Development Pipeline and Future Plans
Building on these encouraging results, Ethris has announced plans to advance ETH47 into Phase 2a clinical trials in the second quarter of 2025. This next phase will specifically evaluate the therapy's effectiveness in asthma patients with rhinovirus infections.
Beyond ETH47, Ethris is leveraging its respiratory mRNA platform to develop treatments for rare genetic disorders. The company's pipeline includes protein replacement therapy candidates for conditions such as primary ciliary dyskinesia (PCD) and pulmonary alveolar proteinosis (PAP), currently in discovery and preclinical stages.
The successful Phase 1 trial represents a significant step forward in the emerging field of inhaled mRNA therapeutics, potentially opening new avenues for treating various respiratory conditions with precise, locally-acting medications.